Biswal A, Agrawal I, Panda M
Indian J Dermatol. 2024; 69(4):366.
PMID: 39296706
PMC: 11407553.
DOI: 10.4103/ijd.ijd_515_23.
Li Y, Zeng Y, Chen Z, Tan X, Mei X, Wu Z
Front Immunol. 2024; 15:1291556.
PMID: 38361944
PMC: 10867127.
DOI: 10.3389/fimmu.2024.1291556.
Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G
Int J Mol Sci. 2023; 24(24).
PMID: 38139134
PMC: 10743634.
DOI: 10.3390/ijms242417306.
Pala V, Ribero S, Quaglino P, Mastorino L
J Clin Med. 2023; 12(23).
PMID: 38068541
PMC: 10707156.
DOI: 10.3390/jcm12237486.
Iwanowski T, Kolkowski K, Nowicki R, Sokolowska-Wojdylo M
Int J Mol Sci. 2023; 24(11).
PMID: 37298700
PMC: 10253679.
DOI: 10.3390/ijms24119749.
Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review.
Ceresnie M, Warbasse E, Gonzalez S, Pourang A, Hamzavi I
Arch Dermatol Res. 2023; 315(8):2233-2259.
PMID: 37029284
DOI: 10.1007/s00403-023-02608-3.
Advances in vitiligo: Update on therapeutic targets.
Feng Y, Lu Y
Front Immunol. 2022; 13:986918.
PMID: 36119071
PMC: 9471423.
DOI: 10.3389/fimmu.2022.986918.
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Glickman J, Del Duca E, Nia J, Hashim P, Singer G
Arch Dermatol Res. 2022; 315(2):181-189.
PMID: 35230488
DOI: 10.1007/s00403-022-02336-0.
Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.
Custurone P, Di Bartolomeo L, Irrera N, Borgia F, Altavilla D, Bitto A
Int J Mol Sci. 2021; 22(21).
PMID: 34768860
PMC: 8584117.
DOI: 10.3390/ijms222111429.
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Migayron L, Boniface K, Seneschal J
Dermatol Ther (Heidelb). 2020; 10(6):1185-1198.
PMID: 32949337
PMC: 7649199.
DOI: 10.1007/s13555-020-00447-y.
IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis.
Badloe F, De Vriese S, Coolens K, Schmidt-Weber C, Ring J, Gutermuth J
Clin Transl Allergy. 2020; 10:34.
PMID: 32774842
PMC: 7398196.
DOI: 10.1186/s13601-020-00338-7.
Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis.
Tajalli M, Kabir S, Vance T, Qureshi A
Clin Case Rep. 2020; 8(5):819-822.
PMID: 32477525
PMC: 7250974.
DOI: 10.1002/ccr3.2759.
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
Montilla A, Gomez-Garcia F, Gomez-Arias P, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B
Dermatol Ther (Heidelb). 2019; 9(4):655-683.
PMID: 31606872
PMC: 6828894.
DOI: 10.1007/s13555-019-00329-y.
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.
Sonthalia S, Aggarwal P
Indian Dermatol Online J. 2019; 10(5):503-518.
PMID: 31544068
PMC: 6743407.
DOI: 10.4103/idoj.IDOJ_474_18.
Home phototherapy for patients with vitiligo: challenges and solutions.
Smith M, Ly K, Thibodeaux Q, Bhutani T, Nakamura M
Clin Cosmet Investig Dermatol. 2019; 12:451-459.
PMID: 31388308
PMC: 6607222.
DOI: 10.2147/CCID.S185798.
New and Emerging Therapies for Pediatric Atopic Dermatitis.
Nguyen H, Anderson K, Tollefson M
Paediatr Drugs. 2019; 21(4):239-260.
PMID: 31364023
DOI: 10.1007/s40272-019-00342-w.
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu S
F1000Res. 2018; 7:82.
PMID: 29399328
PMC: 5773931.
DOI: 10.12688/f1000research.13167.1.
